Mayar Capital Ltd. decreased its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 54.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 27,848 shares of the company’s stock after selling 33,054 shares during the quarter. Johnson & Johnson makes up approximately 4.3% of Mayar Capital Ltd.’s portfolio, making the stock its 11th largest holding. Mayar Capital Ltd.’s holdings in Johnson & Johnson were worth $4,919,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors also recently modified their holdings of the company. Glassy Mountain Advisors Inc. bought a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $35,000. Retirement Financial Solutions LLC bought a new position in Johnson & Johnson during the fourth quarter worth $40,000. TD Capital Management LLC bought a new position in Johnson & Johnson during the third quarter worth $48,000. Iron Horse Wealth Management LLC increased its position in Johnson & Johnson by 112.8% during the fourth quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock worth $53,000 after acquiring an additional 159 shares during the period. Finally, Cowa LLC bought a new position in Johnson & Johnson during the third quarter worth $58,000. Institutional investors own 67.94% of the company’s stock.
Analysts Set New Price Targets
A number of brokerages recently issued reports on JNJ. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $176.00 to $180.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Wednesday, February 1st. UBS Group initiated coverage on shares of Johnson & Johnson in a research note on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price target on the stock. SVB Leerink decreased their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research note on Friday, January 20th. Finally, Citigroup lifted their price target on shares of Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research note on Monday, December 12th. Eight analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $173.67.
Insider Activity at Johnson & Johnson
Johnson & Johnson Stock Up 1.0 %
Shares of NYSE:JNJ opened at $155.00 on Friday. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $186.69. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99. The company’s fifty day moving average is $158.02 and its 200-day moving average is $167.16. The company has a market capitalization of $403.66 billion, a PE ratio of 23.00, a P/E/G ratio of 2.64 and a beta of 0.54.
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.22 by $0.13. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The business had revenue of $23.71 billion during the quarter, compared to analysts’ expectations of $23.90 billion. During the same period in the previous year, the business posted $2.13 earnings per share. The firm’s revenue for the quarter was down 4.4% compared to the same quarter last year. Equities research analysts predict that Johnson & Johnson will post 10.5 earnings per share for the current fiscal year.
Johnson & Johnson Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st were issued a $1.13 dividend. The ex-dividend date was Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.92%. Johnson & Johnson’s dividend payout ratio is 67.06%.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 3/27 – 3/31
- What is a Gold IRA, and is it a Viable Investment?
- Is Braze Inc Ready To Rocket Higher?
- Mullen Automotive Makes Deliveries; Short-Squeeze Possible
- Can Frontline Maintain This Momentum?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
